We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




BD Partners with Mayo Clinic Platform for Access to World's Largest Collection of Clinical Data

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: Mayo Clinic Platform is harnessing new technologies to change how care is provided (Photo courtesy of Mayo Clinic Platform)
Image: Mayo Clinic Platform is harnessing new technologies to change how care is provided (Photo courtesy of Mayo Clinic Platform)

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has entered into a collaboration with Mayo Clinic Platform (Rochester, MN, USA) to access de-identified patient data from Mayo Clinic Platform_Discover to perform detailed post-market surveillance on its products to fuel innovation and unlock a faster, more efficient path to market, with the ultimate goal of improving patient care.

Mayo Clinic Platform_Discover, an enabling product of Mayo Clinic Platform, represents one of the most robust de-identified data sets available from 10 million patients, including both structured and unstructured data, images, 1.2 billion lab test results, three million echocardiograms and more than 640 million clinical notes. Using data mining, next generation artificial intelligence (AI) and machine learning tools, BD will analyze the real-world data - which provides information outside what is typically gathered in a clinical trial - to generate deeper insight into the patient experience that will help the company accelerate and enhance innovation around both existing products and unmet needs.

By using the rich historical data for predictive modelling, BD also will look to make more accurate forecasts related to device use, to increase efficiency for new clinical trials and to generate evidence. BD will also apply the Mayo Clinic data to support new claims for its products and streamline medical device regulatory submissions.

"For years, randomized control trials have been considered the gold-standard in evaluating safety and efficacy for medical devices, but experts from industry and academia who are examining the tight parameters around clinical trials are seeing added value in leveraging insights from real-world data to truly understand whether we are meeting patients' needs," said Lisa Boyle, vice president of global clinical affairs and medical affairs strategy for BD. "We need to be leveraging real-world evidence, using datasets like those from Mayo Clinic Platform, to understand the many parameters that we wouldn't normally capture in a clinical trial and understand patients' care pathways and address the needs of diverse patients in order to establish better solutions for better outcomes and experiences."

"Our next generation analytical tools and curated de-identified patient data create a dynamic, privacy-protected environment for discovery that few in the industry can provide," said Steven Bethke, vice president for product portfolio, Mayo Clinic Platform. "Mayo Clinic Platform_Discover enables medical technology leaders such as BD to derive key insights as they develop solutions for their customers and patients as quickly and safely as possible."

Related Links:
Becton, Dickinson and Company 
Mayo Clinic Platform 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.